199 related articles for article (PubMed ID: 31261173)
21. Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease.
Casonato A; Cattini MG; Daidone V; Pontara E; Bertomoro A; Prandoni P
PLoS One; 2016; 11(8):e0161310. PubMed ID: 27532107
[TBL] [Abstract][Full Text] [Related]
22. Type 1 von Willebrand Disease in a Pediatric Patient Caused by a Novel Heterozygous Deletion of Exons 1 to 6 of the von Willebrand Factor Gene: A Case Report.
Lapić I; Radić Antolic M; Rogić D; Dejanović Bekić S; Coen Herak D; Bilić E; Zadro R
Lab Med; 2023 Jul; 54(4):434-438. PubMed ID: 36468906
[TBL] [Abstract][Full Text] [Related]
23. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
[TBL] [Abstract][Full Text] [Related]
24. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.
Starke RD; Paschalaki KE; Dyer CE; Harrison-Lavoie KJ; Cutler JA; McKinnon TA; Millar CM; Cutler DF; Laffan MA; Randi AM
Blood; 2013 Apr; 121(14):2773-84. PubMed ID: 23355534
[TBL] [Abstract][Full Text] [Related]
25. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
26. Genetic Variation in the Syntaxin-Binding Protein STXBP5 in Type 1 von Willebrand Disease Patients.
Lind-Halldén C; Manderstedt E; Carlberg D; Lethagen S; Halldén C
Thromb Haemost; 2018 Aug; 118(8):1382-1389. PubMed ID: 29972863
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.
Lehmann M; Ashworth K; Manco-Johnson M; Di Paola J; Neeves KB; Ng CJ
J Thromb Haemost; 2018 Jan; 16(1):104-115. PubMed ID: 29064615
[TBL] [Abstract][Full Text] [Related]
28. Controversies in the diagnosis of Type 1 von Willebrand disease.
Bowman ML; James PD
Int J Lab Hematol; 2017 May; 39 Suppl 1():61-68. PubMed ID: 28447419
[TBL] [Abstract][Full Text] [Related]
29. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
30. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease.
Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
J Thromb Haemost; 2021 Jan; 19(1):96-106. PubMed ID: 32998182
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in the C-type lectin receptor CLEC4M in type 1 von Willebrand Disease patients.
Manderstedt E; Lind-Halldén C; Lethagen S; Halldén C
PLoS One; 2018; 13(2):e0192024. PubMed ID: 29389944
[TBL] [Abstract][Full Text] [Related]
32. The molecular characterization of von Willebrand disease: good in parts.
James PD; Lillicrap D
Br J Haematol; 2013 Apr; 161(2):166-76. PubMed ID: 23406206
[TBL] [Abstract][Full Text] [Related]
33. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of von Willebrand disease in Australia.
Favaloro EJ; Bonar R; Favaloro J; Koutts J
Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
[TBL] [Abstract][Full Text] [Related]
35. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study.
James PD; Paterson AD; Notley C; Cameron C; Hegadorn C; Tinlin S; Brown C; O'Brien L; Leggo J; Lillicrap D;
J Thromb Haemost; 2006 Apr; 4(4):783-92. PubMed ID: 16634747
[TBL] [Abstract][Full Text] [Related]
36. Low von Willebrand factor: sometimes a risk factor and sometimes a disease.
Sadler JE
Hematology Am Soc Hematol Educ Program; 2009; ():106-12. PubMed ID: 20008188
[TBL] [Abstract][Full Text] [Related]
37. The common VWF variant p.Y1584C: detailed pathogenic examination of an enigmatic sequence change.
Christopherson PA; Tijet N; Haberichter SL; Flood VH; Ross J; Notley C; Rawley O; Montgomery RR; ; James PD; Lillicrap D
J Thromb Haemost; 2024 Mar; 22(3):666-675. PubMed ID: 38040335
[TBL] [Abstract][Full Text] [Related]
38. The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease.
Seaman CD; Ragni MV
Clin Appl Thromb Hemost; 2018 Apr; 24(3):434-438. PubMed ID: 28874064
[TBL] [Abstract][Full Text] [Related]
39. Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism.
Hawke L; Bowman ML; Poon MC; Scully MF; Rivard GE; James PD
Blood; 2016 Jul; 128(4):584-93. PubMed ID: 27317792
[TBL] [Abstract][Full Text] [Related]
40. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels.
Bucciarelli P; Siboni SM; Stufano F; Biguzzi E; Canciani MT; Baronciani L; Pagliari MT; La Marca S; Mistretta C; Rosendaal FR; Peyvandi F
J Thromb Haemost; 2015 Feb; 13(2):228-36. PubMed ID: 25425019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
